Market Trends– category –
-
Pharmaceutical CDMO Market Report: Capital Investments and Advanced Therapies Drive Growth
Global Market Insights Global Overview This article provides an overview of the Pharmaceutical CDMO Market research report published by Global Market Insights. The report highlights significant capital investments and major expansions wi... -
Cell Therapy Startups Like Orca Bio and Allogene Lead Cancer & Autoimmune Disease Treatment with Off-the-Shelf Platforms
New Market Pitch USA Overview Cell therapy startups such as Orca Bio and Allogene, utilizing off-the-shelf platforms, are spearheading advancements in allogeneic and iPSC-derived therapies for cancer and autoimmune diseases. Key differen... -
Genedata Establishes New Standard for Biopharma Quality Control with NGS, Ensuring Genetic Stability in CGT
Genedata Switzerland Overview Genedata highlights Next-Generation Sequencing (NGS) as a powerful analytical tool for biopharmaceutical quality control (QC). NGS offers GxP-compliant workflows and supports data integrity and streamlined c... -
Data Integrity and ALCOA+ Compliance Critical for Bioprocessing Lab Managers: Addressing Regulatory Requirements with Digital Solutions
LabManager.com USA Overview An article highlights the critical importance of data integrity and ALCOA+ compliance for bioprocessing lab managers. Maintaining ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, C... -
Bispecific Antibody CDMO Market to Surge to $603.13 Billion by 2035, Driven by Diverse Asymmetric Formats
PharmaSource UK Overview This article outlines a market research report from PharmaSource on the bispecific antibody CDMO market, projected to skyrocket from $25.94 billion in 2026 to approximately $603.13 billion by 2035. A key market t... -
EU NK Cell Market Projected for Twofold Growth by 2035, Driven by Increasing Allogeneic NK Cell Therapy Approvals
IndexBox USA Overview This article outlines a report from IndexBox on the European Union's NK cell market, which is expected to double in size between 2026 and 2035. This growth is primarily driven by the approval and commercial launch o... -
Biologics CDMO Market Competitive Landscape Report: Lonza, Samsung Biologics, and WuXi Biologics Drive Growth
National Law Review USA Overview This article summarizes a report on the competitive landscape and growth drivers of the biologics CDMO market. Key players include Lonza Group Ltd, Samsung Biologics Co Ltd, WuXi Biologics Cayman Inc, The... -
U.S. Stem Cell Manufacturing Market Forecast to Reach $4.04 Billion, Driven by Innovative Technologies and Automation from Thermo Fisher, Lonza, and Sartorius
openPR.com USA Overview This article summarizes a report on the U.S. stem cell manufacturing market, projected to reach $4.04 billion, driven by innovative technologies and strategic initiatives from key players. Thermo Fisher Scientific... -
WuXi Biologics Suzhou BioSafety Testing Center Secures Fourth EMA GMP Certification, Enabling 19 Commercial Products for European Market
WuXi Biologics China Overview WuXi Biologics' Suzhou BioSafety Testing Center has successfully renewed its European Medicines Agency (EMA) GMP certification for the fourth time. This accreditation enables the center to support quality te... -
CDMO Signal Ranks Lentiviral Vector (LVV) CDMOs: GMP Standards and Robust Assays Key for Selection
CDMO Signal USA Overview CDMO Signal published its ranking of Lentiviral Vector (LVV) CDMOs based on Signal Score. LVVs are critical in ex vivo gene therapies for engineering CAR-T cells and modifying hematopoietic stem cells, necessitat...
